Search

Your search keyword '"Luis Gros Subias"' showing total 4 results
Start Over Author "Luis Gros Subias"
4 results on '"Luis Gros Subias"'

1. A phase 1, first-in-child, multicenter study to evaluate the safety and efficacy of the oncolytic herpes virus talimogene laherparepvec in pediatric patients with advanced solid tumors

Author

Lucas Moreno, Pierre Teira, James M. Croop, Nicolas U. Gerber, Nicolas André, Isabelle Aerts, Luis Gros Subias, Bram De Wilde, Francisco Bautista, Brian Turpin, Srinivasa Kunduri, Ali Hamidi, Tatiana Lawrence, and Keri A. Streby

Subjects
immunotherapy, pediatric solid tumor, talimogene laherparepvec, non-CNS tumors, relapsed and refractory cancer, oncolytic herpes virus, Pediatrics, RJ1-570
Abstract

BackgroundThe survival rates for pediatric patients with relapsed and refractory tumors are poor. Successful treatment strategies are currently lacking and there remains an unmet need for novel therapies for these patients. We report here the results of a phase 1 study of talimogene laherparepvec (T-VEC) and explore the safety of this oncolytic immunotherapy for the treatment of pediatric patients with advanced non–central nervous system tumors.MethodsT-VEC was delivered by intralesional injection at 106 plaque-forming units (PFU)/ml on the first day, followed by 108 PFU/ml on the first day of week 4 and every 2 weeks thereafter. The primary objective was to evaluate the safety and tolerability as assessed by the incidence of dose-limiting toxicities (DLTs). Secondary objectives included efficacy indicated by response and survival per modified immune-related response criteria simulating the Response Evaluation Criteria in Solid Tumors (irRC-RECIST).ResultsFifteen patients were enrolled into two cohorts based on age: cohort A1 (n = 13) 12 to ≤21 years old (soft-tissue sarcoma, n = 7; bone sarcoma, n = 3; neuroblastoma, n = 1; nasopharyngeal carcinoma, n = 1; and melanoma, n = 1) and cohort B1 (n = 2) 2 to

Published
2023
Full Text
View/download PDF

2. Malignant vaginal tumor: About a case

Author

Mariona Morell Daniel, María Rosario Pérez-Torres Lobato, Miriam Morey Olivé, Luis Gros Subias, Institut Català de la Salut, Servei d'Hematologia i Oncologia Pediàtriques, Vall d’Hebron Hospital Universitari, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
Management of Technology and Innovation, Other subheadings::/diagnosis [Other subheadings], Otros calificadores::/diagnóstico [Otros calificadores], Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Genital Neoplasms, Female::Vaginal Neoplasms [DISEASES], neoplasias::neoplasias por localización::neoplasias urogenitales::neoplasias de los genitales femeninos::neoplasias vaginales [ENFERMEDADES], Vagina - Càncer - Diagnòstic
Abstract

Malignant vaginal tumor Tumor maligno de vagina Tumor vaginal maligne

Published
2023

4. Epstein–Barr virus‐associated risk factors for post‐transplant lymphoproliferative disease in pediatric liver transplant recipients

Author

Jesus Quintero Bernabeu, Javier Juamperez, Maria Mercadal‐Hally, Mauricio Larrarte King, Soledad Gallego Melcon, Luis Gros Subias, Constantino Sábado Álvarez, Pere Soler‐Palacin, Susana Melendo Pérez, Juliana Esperalba, Alexandra Navarro Jiménez, Marta Garrido Pontnou, Jessica Camacho Soriano, Ernest Hidalgo Llompart, Itxarone Bilbao Aguirre, and Ramón Charco Torra

Subjects
Epstein-Barr Virus Infections, Herpesvirus 4, Human, Transplantation, Postoperative Complications, Risk Factors, DNA, Viral, Pediatrics, Perinatology and Child Health, Humans, Viral Load, Child, Lymphoproliferative Disorders, Liver Transplantation
Abstract

Post-transplant lymphoproliferative disorder (PTLD) are the most common de novo malignancies after liver transplantation (LT) in children. The aim of our study was to assess the role of pre-LT EBV status and post-LT EBV viral load as risk factors for developing PTLD in a cohort of pediatric LT recipients.Data of all children who underwent LT between January 2002 and December 2019 were collected. Two cohorts were built EBV pre-LT primary infected cohort and EBV post-LT primary infected cohort. Moreover, using the maximal EBV viral load, a ROC curve was constructed to find a cutoff point for the diagnosis of PTLD.Among the 251 patients included in the study, fifteen PTLD episodes in 14 LT recipients were detected (2 plasmacytic hyperplasia, 10 polymorphic PTLD, 2 monomorphic PTLD, and 1 Classical-Hodgkin's lymphoma). Patients of the EBV post-LT primary infected cohort were 17.1 times more likely to develop a PTLD than patients of the EBV pre-LT primary infected cohort (2.2-133.5). The EBV viral load value to predict PTLD was set at 211 000 UI/mL (93.3% sensitivity and 77.1% specificity; AUC 93.8%; IC 0.89-0.98). In EBV post-LT primary infected cohort, patients with a viral load above 211 000 were 30 times more likely to develop PTLD than patients with a viral load below this value (OR 29.8; 3.7-241.1; p 0.001).The combination of pretransplant EBV serological status with EBV post-transplant viral load could be a powerful tool to stratify the risk of PTLD in pediatric LT patients.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results